Does the media favor OLMA or INDV?

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 2 articles in the media. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Indivior's score of 0.87 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, OLMA or MANE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A Veradermics N/A N/A N/A N/A N/A

Is OLMA or MANE more profitable?

Veradermics' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Veradermics N/A N/A N/A

Does the media prefer OLMA or MANE?

In the previous week, Veradermics had 6 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 8 mentions for Veradermics and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Veradermics' score of 0.34 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OLMA or AMRX?

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 2 articles in the media. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Amneal Pharmaceuticals' score of 0.72 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TVTX or OLMA?

In the previous week, Travere Therapeutics had 7 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 9 mentions for Travere Therapeutics and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Travere Therapeutics' score of 0.59 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Olema Pharmaceuticals (OLMA) Competitors

$10.51 -0.18 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$10.52 +0.01 (+0.10%)

As of 07:00 PM Eastern

Compare

OLMA vs. INDV, MANE, AMRX, TVTX, and TWST

Should you buy Olema Pharmaceuticals stock or one of its competitors? MarketBeat compares Olema Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Olema Pharmaceuticals include Indivior (INDV), Veradermics (MANE), Amneal Pharmaceuticals (AMRX), Travere Therapeutics (TVTX), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

How does Olema Pharmaceuticals compare to Indivior?

Olema Pharmaceuticals (NASDAQ:OLMA) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Olema Pharmaceuticals currently has a consensus price target of $44.10, suggesting a potential upside of 319.60%. Indivior has a consensus price target of $39.33, suggesting a potential upside of 11.02%. Given Olema Pharmaceuticals' higher possible upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Indivior	$1.24B	3.49	$210M	$1.95	18.17

Olema Pharmaceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Indivior has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Indivior has a net margin of 19.44% compared to Olema Pharmaceuticals' net margin of 0.00%. Olema Pharmaceuticals' return on equity of -46.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Indivior	19.44%	-219.26%	29.40%

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 2 articles in the media. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Indivior's score of 0.87 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Olema Pharmaceuticals and Indivior tied by winning 7 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Veradermics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

Veradermics' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Veradermics	N/A	N/A	N/A

In the previous week, Veradermics had 6 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 8 mentions for Veradermics and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Veradermics' score of 0.34 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Olema Pharmaceuticals presently has a consensus price target of $44.10, indicating a potential upside of 319.60%. Veradermics has a consensus price target of $109.00, indicating a potential upside of 12.37%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Olema Pharmaceuticals beats Veradermics on 6 of the 9 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Amneal Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Olema Pharmaceuticals' net margin of 0.00%. Olema Pharmaceuticals' return on equity of -46.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 2 articles in the media. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Amneal Pharmaceuticals' score of 0.72 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Olema Pharmaceuticals presently has a consensus target price of $44.10, suggesting a potential upside of 319.60%. Amneal Pharmaceuticals has a consensus target price of $15.17, suggesting a potential upside of 17.75%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amneal Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Amneal Pharmaceuticals	$3.02B	1.36	$72.06M	$0.38	33.89

Summary

Amneal Pharmaceuticals beats Olema Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Olema Pharmaceuticals has a net margin of 0.00% compared to Travere Therapeutics' net margin of -4.00%. Travere Therapeutics' return on equity of -26.16% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

In the previous week, Travere Therapeutics had 7 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 9 mentions for Travere Therapeutics and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Travere Therapeutics' score of 0.59 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

Travere Therapeutics presently has a consensus target price of $48.92, suggesting a potential upside of 8.22%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 319.60%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Travere Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Travere Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	8.57	-$25.55M	-$0.23	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Olema Pharmaceuticals beats Travere Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Twist Bioscience?

Olema Pharmaceuticals (NASDAQ:OLMA) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Olema Pharmaceuticals has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market.

Olema Pharmaceuticals presently has a consensus target price of $44.10, suggesting a potential upside of 319.60%. Twist Bioscience has a consensus target price of $58.00, suggesting a potential downside of 19.81%. Given Olema Pharmaceuticals' higher probable upside, equities analysts plainly believe Olema Pharmaceuticals is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Twist Bioscience has higher revenue and earnings than Olema Pharmaceuticals. Twist Bioscience is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Twist Bioscience	$376.57M	11.96	-$77.67M	-$1.33	N/A

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 2 mentions for Olema Pharmaceuticals and 1 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.38 beat Olema Pharmaceuticals' score of 0.96 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Olema Pharmaceuticals	Positive
Twist Bioscience	Positive

Olema Pharmaceuticals has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Summary

Twist Bioscience beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$933.74M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	N/A	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	1.79	6.63	9.84	6.72
Net Income	-$162.45M	$24.20M	$3.57B	$337.19M
7 Day Performance	-18.59%	-3.24%	-1.16%	0.48%
1 Month Performance	-26.61%	0.53%	3.85%	5.07%
1 Year Performance	159.51%	47.24%	27.40%	34.25%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	3.1894 of 5 stars	$10.51 -1.7%	$44.10 +319.6%	+144.1%	$933.74M	N/A	N/A	70
INDV Indivior	3.2458 of 5 stars	$33.55 -6.9%	$39.33 +17.3%	+170.5%	$4.39B	$1.24B	17.46	1,051
MANE Veradermics	N/A	$100.43 -0.5%	$109.00 +8.5%	N/A	$4.26B	N/A	N/A	19	Analyst Forecast Gap Up
AMRX Amneal Pharmaceuticals	3.9972 of 5 stars	$12.72 -3.4%	$15.17 +19.3%	+70.5%	$4.20B	$3.05B	33.50	8,500
TVTX Travere Therapeutics	2.0161 of 5 stars	$43.57 -7.6%	$47.83 +9.8%	+176.7%	$4.19B	$536.20M	N/A	460	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. INDV, MANE, AMRX, TVTX, and TWST

How does Olema Pharmaceuticals compare to Indivior?

Summary

How does Olema Pharmaceuticals compare to Veradermics?

Summary

How does Olema Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does Olema Pharmaceuticals compare to Travere Therapeutics?

Summary

How does Olema Pharmaceuticals compare to Twist Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. INDV, MANE, AMRX, TVTX, and TWST

How does Olema Pharmaceuticals compare to Indivior?

Do institutionals and insiders hold more shares of OLMA or INDV?

Do analysts rate OLMA or INDV?

Which has higher earnings and valuation, OLMA or INDV?

Which has more risk and volatility, OLMA or INDV?

Is OLMA or INDV more profitable?

Does the media favor OLMA or INDV?

Summary

How does Olema Pharmaceuticals compare to Veradermics?

Which has preferable earnings and valuation, OLMA or MANE?

Is OLMA or MANE more profitable?

Does the media prefer OLMA or MANE?

Do analysts rate OLMA or MANE?

Do insiders & institutionals have more ownership in OLMA or MANE?

Summary

How does Olema Pharmaceuticals compare to Amneal Pharmaceuticals?

Is OLMA or AMRX more profitable?

Does the media favor OLMA or AMRX?

Which has more risk & volatility, OLMA or AMRX?

Do analysts prefer OLMA or AMRX?

Do insiders and institutionals hold more shares of OLMA or AMRX?

Which has stronger valuation and earnings, OLMA or AMRX?

Summary

How does Olema Pharmaceuticals compare to Travere Therapeutics?

Is TVTX or OLMA more profitable?

Does the media favor TVTX or OLMA?

Which has more volatility and risk, TVTX or OLMA?

Do analysts prefer TVTX or OLMA?

Which has higher earnings and valuation, TVTX or OLMA?

Do institutionals and insiders hold more shares of TVTX or OLMA?

Summary

How does Olema Pharmaceuticals compare to Twist Bioscience?

Which has more risk and volatility, OLMA or TWST?

Do analysts recommend OLMA or TWST?

Which has preferable earnings & valuation, OLMA or TWST?

Do institutionals & insiders hold more shares of OLMA or TWST?

Does the media favor OLMA or TWST?

Is OLMA or TWST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools